3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
9
Tumor-Agnostic
2
Thoracic
2
Gynecologic
2
Genitourinary
2
Head & Neck
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous-Cell Non-Small-Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
Carboplatin
1152
Cisplatin
876
Pemetrexed
834
pembrolizumab
608
Paclitaxel
598
Docetaxel
535
Gemcitabine
424
Radiotherapy
377
Erlotinib Hydrochloride
367
Nivolumab
322
Bevacizumab
322
Etoposide
295
durvalumab
254
Drug Therapy
233
osimertinib
218
atezolizumab
208
Radiosurgery
190
Gefitinib
177
Vinorelbine
145
130-nm albumin-bound paclitaxel
124
Magnetic Resonance Spectroscopy
121
Ipilimumab
118
Cetuximab
113
anlotinib
104
tislelizumab
103
Topotecan
101
Cyclophosphamide
101
Taxes
99
Irinotecan
95
Albumin-Bound Paclitaxel
92
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
bemarituzumab
×
Thoracic
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled
NCT05267470
2025-03-25
FORTITUDE-201
Amgen
Phase 1
Terminated
74 enrolled
22 charts